My background includes over 25 years in the area of computational chemistry. I spent eight years at GlaxoSmithKline Pharmaceuticals doing computational chemistry in support of a number of drug discovery projects in oncology (AKT kinase), anti-infective and cardiovascular therapeutic areas. During the thirteen years at OpenEye Scientific, I worked on validation and development of new and/or enhancements to computational methods. More recently I returned to drug discovery within the biotech environment.While at GlaxoSmithKline, my tasks included using structure- and ligand-based computational methods for lead discovery and optimization, development of a new peptide mimetic method using torsion-angle molecular dynamics, data mining of HTS data for lead identification by building binary QSAR models, and the deployment of a site-wide combinatorial library docking infrastructure. The contributions I made while at GSK resulted in two granted patents, three publications (AKT kinase and urotensin II receptor antagonists), and four impact awards over the eight years I was employed.At OpenEye, I have been involved in extensive validation studies of new and improvements to existing software for ligand- and structure-based drug design. Much of this work was reported to customers through presentations, white papers, at conferences and in publications. My particular focus has been on pose prediction, binding site comparison, and ligand fitting to X-ray crystallographic data. Another area explored was validation of solvent mapping methods and and free energy calculations and using those learnings to drive de novo lead optimization of fragment leads.I joined the drug discovery team at DeepCure where we are using predictive AI technology to improve the breadth and accuracy of pre-clinical drug discovery in 2019.In 2022 I joined a chemistry platform precision oncology company as the head of computational chemistry.In 2023 I had the pleasure of joining Osmo, an AI company, working towards giving computers a sense of smell.